METIS TECHBIO-P's stock plummeted 5.50% intraday on Friday, extending a multi-day decline from its recent listing highs.

The decline is part of a sustained post-IPO correction as initial enthusiasm for the new listing fades. The company, which debuted on the Hong Kong Stock Exchange earlier this month after branding itself as the world's first AI drug delivery company to go public, remains in an early commercialization stage. It has accumulated significant losses over the past three years with volatile revenue, leaving its growth outlook unproven. Additionally, some internationally placed shares carry no lock-up period, creating persistent profit-taking pressure.

METIS TECHBIO-P focuses on AI-driven nanomaterial innovation for targeted drug delivery and discovery technologies, aiming to accelerate therapies for critical disease areas including oncology, metabolic disorders, autoimmune diseases, and neurodegenerative conditions.